TREVENA INC (TRVN)

Company Profile

Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. The company is headquartered in Chesterbrook, Pennsylvania and currently employs 23 full-time employees. The company went IPO on 2014-01-31. The firm has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).

Company Info

TREVENA INC

955 Chesterbrook Boulevard, Suite 110

Chesterbrook PENNSYLVANIA 19087

P: 16103548840

CEO: Carrie L. Bourdow

Employees: 23

Website: https://www.trevena.com/